Anika Announces Data Presentation and Symposium on CINGAL at 2017 EFORT Annual Congress
May 30 2017 - 4:05PM
Business Wire
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
orthopedics medicines company specializing in therapeutics based on
its proprietary hyaluronic acid ("HA") technology, today announced
plans to present Phase III data on CINGAL®, its novel
HA-corticosteroid combination viscosupplement, at the 2017 European
Federation of National Associations of Orthopedics and Traumatology
(EFORT) Annual Congress. CINGAL is CE marked for the treatment of
symptoms associated with osteoarthritis (“OA”) of the knee, and is
pending regulatory review in the United States. The EFORT Annual
Congress is Europe’s largest and most prestigious gathering of
orthopedists and will be held at the Messe Wien Exhibition &
Congress Center in Vienna, Austria from May 31 through June 2.
“We are excited to showcase data on our novel hyaluronic acid
and corticosteroid combination viscosupplement, CINGAL, along with
our extensive portfolio of treatments for joint and tendon pain, at
the premier meeting of European orthopedists,” said Charles H.
Sherwood, Ph.D., President and Chief Executive Officer of Anika
Therapeutics. “Since its launch in Europe and Canada last year,
CINGAL has received an overwhelmingly positive response from
physicians owed to its clinically proven ability to provide
immediate and long-term relief from knee OA symptoms for 6 months
and potentially beyond. The EFORT Annual Congress is an ideal
opportunity for us to share our early clinical experience and
published data with physicians from across Europe.”
CINGAL is the first and only viscosupplement that combines
triamcinolone hexacetonide, a well-established, FDA-approved
steroid that may be utilized to treat inflammation, with Anika’s
proprietary cross-linked, non-animal-derived hyaluronic acid, which
is the active "cushioning" ingredient in the global market-leading
viscosupplements, ORTHOVISC® and MONOVISC®. Viscosupplements are
injected by a licensed medical professional into synovial joints to
replenish the natural cushioning within joints that depletes with
age and degenerative orthopedic diseases, causing pain. In addition
to showcasing its viscosupplementation offerings, Anika’s booth at
the congress will also include its newest product Orthovisc-T, a CE
marked treatment indicated to relieve pain and restore function in
tendons affected by chronic lateral epicondylosis.
CINGAL Data Poster Presentation
Wednesday, May 31, 2017
- Intraarticular Injection of a
Cross-Linked Sodium Hyaluronate Combined with Triamcinolone
Hexacetonide (CINGAL) to Provide Symptomatic Relief of
Osteoarthritis of the Knee: A Randomized, Double-Blind,
Placebo-Controlled Multicenter Clinical Trial (Authors: Dr. Laszlo
Hangody, et al.)
CINGAL Company-Sponsored Symposium
Thursday, June 1, 2017 at 6 pm at
Courtyard Marriott Vienna Prater/Messe
- Double-blind, Randomized, Comparative
Evaluation of Clinical Efficacy and Early Clinical Experience with
CINGAL Intraarticular Injection (Lead Presenter: Dr. L.
Hangody)
If you are attending the conference, please visit Anika at
Booth #B21
About EFORT
The European Federation of National Associations of Orthopedics
and Traumatology (EFORT) is the umbrella organization linking
Europe's national orthopedic societies. EFORT was founded in 1991
in the Italian Marentino. Today it has 41 national member societies
and 13 associate scientific members. EFORT is a non-profit
organization. The participating societies aim at promoting the
exchange of scientific knowledge and experience in the prevention
and treatment of diseases and injuries of the musculoskeletal
system. EFORT organizes an annual congress, seminars, courses,
forums and conferences within Europe. It also initiates and
supports basic and clinical research. The EFFORT Annual Congress is
the largest platform for European Orthopedics to exchange knowledge
and experience within Europe but also with colleagues from other
parts of the world.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated
orthopedic medicines company based in Bedford, Massachusetts. Anika
is committed to improving the lives of patients with degenerative
orthopedic diseases and traumatic conditions with clinically
meaningful therapies along the continuum of care, from palliative
pain management to regenerative cartilage repair. The Company has
over two decades of global expertise developing, manufacturing, and
commercializing more than 20 products based on its proprietary
hyaluronic acid (HA) technology. Anika's orthopedic medicine
portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate
pain and restore joint function by replenishing depleted HA, and
HYALOFAST®, a solid HA-based scaffold to aid cartilage repair and
regeneration. For more information about Anika, please visit
www.anikatherapeutics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170530005609/en/
For Investor Inquiries:Anika Therapeutics, Inc.Sylvia Cheung,
781-457-9000Chief Financial OfficerorFor Media Inquiries:Pure
CommunicationsSonal Vasudev, 917-523-1418
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024